Skip to content

Pharmaceutical Benefits Advisory Committee recommends mifepristone (RU486) be listed on the PBS

The Pharmaceutical Benefits Advisory Committee has recommended that mifepristone (RU486) and another drug taken in conjunction, misoprostol, be covered by the Pharmaceutical Benefits Scheme. In the coming weeks the Government will consider the recommendation and a decision is expected to be made prior to the election. More information is available here.

Subscribe to our weekly e-Bulletin.

Like to receive AFMW news direct to your email? Please enter your details below to join our list. Please note subscribing to our mailing list does not confer AFMW membership.

* indicates required